Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge

Cancer Treatment Reviews

Volumn 50, Issue , 2016, Pages 118-128

  Kandula, Tejaswi ^a,b   Park, Susanna B ^a,c   Cohn, Richard J ^a,b   Krishnan, Arun V ^a   Farrar, Michelle A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer survivorship; Chemotherapy complication; Chemotherapy induced peripheral neuropathy; Peripheral neuropathy; Systematic review

Indexed keywords

BORTEZOMIB; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; IMMUNOGLOBULIN; IXABEPILONE; OXALIPLATIN; PACLITAXEL; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

AGE DISTRIBUTION; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SAFETY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIATION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; AGE; CHEMICALLY INDUCED; CHILD; DISEASE COURSE; NEOPLASMS; NEUROTOXICITY SYNDROMES; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTOR;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; DISEASE PROGRESSION; HUMANS; INCIDENCE; NEOPLASMS; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 84988474448     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.09.005     Document Type: Review

References (78)

1. [1] Kaatsch, P., Epidemiology of childhood cancer. Cancer Treat Rev 36 (2010), 277–285.
2. [2] Phillips, S.M., Padgett, L.S., Leisenring, W.M., Stratton, K.K., Bishop, K., Krull, K.R., et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 24 (2015), 653–663.
3. [3] Park, S.B., Goldstein, D., Krishnan, A.V., Lin, C.S., Friedlander, M.L., Cassidy, J., et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin 63 (2013), 419–437.
4. [4] Kmet LM, Lee RC, Cook LS. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta Heritage Foundation for Medical Research; 2004.
5. [5] Ebell, M.H., Siwek, J., Weiss, B.D., Woolf, S.H., Susman, J., Ewigman, B., et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 69 (2004), 548–556.
6. [6] Courtemanche, H., Magot, A., Ollivier, Y., Rialland, F., Leclair-Visonneau, L., Fayet, G., et al. Vincristine-induced neuropathy: A typical electrophysiological patterns in children. Muscle Nerve 52 (2015), 981–985.
7. [7] Purser, M.J., Johnston, D.L., McMillan, H.J., Chemotherapy-induced peripheral neuropathy among paediatric oncology patients. Can J Neurol Sci - Le Journal Canadien des Sciences Neurologiques 41 (2014), 442–447.
8. [8] Arzanian, M.T., Mehdizadeh, M., Zamani, G.R., Vincristine induced neurotoxicity: Study of 75 cases. Iran J Child Neurol 3 (2009), 39–44.
9. [9] Toopchizadeh, V., Barzegar, M., Rezamand, A., Feiz, A.H., Electrophysiological consequences of vincristine contained chemotherapy in children: A cohort study. J Pediatr Neurol 7 (2009), 351–356.
10. [10] Anghelescu, D.L., Faughnan, L.G., Jeha, S., Relling, M.V., Hinds, P.S., Sandlund, J.T., et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57 (2011), 1147–1153.
11. [11] Lavoie Smith, E.M., Li, L., Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst 20 (2015), 37–46.
12. [12] Bay, A., Yilmaz, C., Yilmaz, N., Oner, A.F., Vincristine induced cranial polyneuropathy. Indian J Pediatr 73 (2006), 531–533.
13. [13] Teichmann, K.D., Dabbagh, N., Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma. J Ocul Pharmacol 4 (1988), 117–121.
14. [14] Egbelakin, A., Ferguson, M.J., MacGill, E.A., Lehmann, A.S., Topletz, A.R., Quinney, S.K., et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56 (2011), 361–367.
15. [15] Langholz, B., Skolnik, J.M., Barrett, J.S., Renbarger, J., Seibel, N.L., Zajicek, A., et al. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. Pediatr Blood Cancer 57 (2011), 252–257.
16. [16] Harila-Saari, A.H., Huuskonen, U.E., Tolonen, U., Vainionpaa, L.K., Lanning, B.M., Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials. Med Pediatr Oncol 36 (2001), 345–351.
17. [17] Vainionpaa, L., Kovala, T., Tolonen, U., Lanning, M., Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve. Pediatr Neurol 13 (1995), 314–318.
18. [18] Fagundes Loss, J., Albino Santos, P.P., Di Leone, L., Lunardi, Brunetto A., Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil. Pediatr Blood Cancer 42 (2004), 139–144.
19. [19] Beaty, O., Berg, S., Blaney, S., Malogolowkin, M., Krailo, M., Knight, R., et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 55 (2010), 440–445.
20. [20] Geoerger, B., Chisholm, J., Le Deley, M.C., Gentet, J.C., Zwaan, C.M., Dias, N., et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. Eur J Cancer 47 (2011), 230–238.
21. [21] Geoerger, B., Doz, F., Gentet, J.C., Mayer, M., Landman-Parker, J., Pichon, F., et al. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol 26 (2008), 4394–4400.
22. [22] Spunt, S.L., Freeman, B.B. 3rd, Billups, C.A., McPherson, V., Khan, R.B., Pratt, C.B., et al. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol: Official Journal of the American Society of Clinical Oncology 25 (2007), 2274–2280.
23. [23] Fouladi, M., Blaney, S.M., Poussaint, T.Y., Freeman, B.B. 3rd, McLendon, R., Fuller, C., et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer 107 (2006), 2291–2297.
24. [24] Macy, M.E., Duncan, T., Whitlock, J., Hunger, S.P., Boklan, J., Narendren, A., et al. A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer 60 (2013), 230–236.
25. [25] Hayashi, R.J., Blaney, S., Sullivan, J., Weitman, S., Vietti, T., Bernstein, M.L., et al. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 25 (2003), 539–542.
26. [26] Horton, T.M., Ames, M.M., Reid, J.M., Krailo, M.D., Pendergrass, T., Mosher, R., et al. A phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer 50 (2008), 788–792.
27. [27] Hurwitz, C.A., Relling, M.V., Weitman, S.D., Ravindranath, Y., Vietti, T.J., Strother, D.R., et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 11 (1993), 2324–2329.
28. [28] Doz, F., Gentet, J.C., Pein, F., Frappaz, D., Chastagner, P., Moretti, S., et al. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer 84 (2001), 604–610.
29. [29] Geller, J.I., Wall, D., Perentesis, J., Blaney, S.M., Bernstein, M., Pediatric Oncology Group s. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer 52 (2009), 346–350.
30. [30] Blaney, S.M., Seibel, N.L., O'Brien, M., Reaman, G.H., Berg, S.L., Adamson, P.C., et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 15 (1997), 1538–1543.
31. [31] Seibel, N.L., Blaney, S.M., O'Brien, M., Krailo, M., Hutchinson, R., Mosher, R.B., et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 5 (1999), 733–737.
32. [32] Yoon, J.H., Kwon, M.M., Park, H.J., Park, S.Y., Lim, K.Y., Joo, J., et al. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. BMC Cancer, 14, 2014, 622.
33. [33] Zwerdling, T., Krailo, M., Monteleone, P., Byrd, R., Sato, J., Dunaway, R., et al. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the children's oncology group. Cancer 106 (2006), 1821–1828.
34. [34] Jacobs, S., Fox, E., Krailo, M., Hartley, G., Navid, F., Wexler, L., et al. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res 16 (2010), 750–754.
35. [35] Widemann, B.C., Goodspeed, W., Goodwin, A., Fojo, T., Balis, F.M., Fox, E., Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol 27 (2009), 550–556.
36. [36] Blaney, S.M., Bernstein, M., Neville, K., Ginsberg, J., Kitchen, B., Horton, T., et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol: Official Journal of the American Society of Clinical Oncology 22 (2004), 4804–4809.
37. [37] Horton, T.M., Perentesis, J.P., Gamis, A.S., Alonzo, T.A., Gerbing, R.B., Ballard, J., et al. A phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 61 (2014), 1754–1760.
38. [38] Muscal, J.A., Thompson, P.A., Horton, T.M., Ingle, A.M., Ahern, C.H., McGovern, R.M., et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer 60 (2013), 390–395.
39. [39] Lazzerini, M., Martelossi, S., Magazzu, G., Pellegrino, S., Lucanto, M.C., Barabino, A., et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 310 (2013), 2164–2173.
40. [40] Lazzerini, M., Martelossi, S., Magazzu, G., Pellegrino, S., Lucanto, M.C., Barabino, A., et al. Effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: Pilot randomized clinical trial. Inflamm Bowel Dis 21 (2015), 1739–1749.
41. [41] Priolo, T., Lamba, L.D., Giribaldi, G., De Negri, E., Grosso, P., De Grandis, E., et al. Childhood thalidomide neuropathy: a clinical and neurophysiologic study. Pediatr Neurol 38 (2008), 196–199.
42. [42] Fleming, F.J., Vytopil, M., Chaitow, J., Jones, H.R. Jr., Darras, B.T., Ryan, M.M., Thalidomide neuropathy in childhood. Neuromuscul Disord 15 (2005), 172–176.
43. [43] Jain, P., Gulati, S., Seth, R., Bakhshi, S., Toteja, G.S., Pandey, R.M., Vincristine-induced neuropathy in childhood ALL (Acute Lymphoblastic Leukemia) survivors: Prevalence and electrophysiological characteristics. J Child Neurol 29 (2014), 932–937.
44. [44] Ramchandren, S., Leonard, M., Mody, R.J., Donohue, J.E., Moyer, J., Hutchinson, R., et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst: JPNS 14 (2009), 184–189.
45. [45] Harila-Saari, A.H., Vainionpaa, L.K., Kovala, T.T., Tolonen, E.U., Lanning, B.M., Nerve lesions after therapy for childhood acute lymphoblastic leukemia. Cancer 82 (1998), 200–207.
46. [46] Lehtinen, S.S., Huuskonen, U.E., Harila-Saari, A.H., Tolonen, U., Vainionpaa, L.K., Lanning, B.M., Motor nervous system impairment persists in long-term survivors of childhood acute lymphoblastic leukemia. Cancer 94 (2002), 2466–2473.
47. [47] Earl, H.M., Connolly, S., Latoufis, C., Eagle, K., Ash, C.M., Fowler, C., et al. Long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas. Sarcoma 2 (1998), 97–105.
48. [48] Ness, K.K., Hudson, M.M., Pui, C.H., Green, D.M., Krull, K.R., Huang, T.T., et al. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer 118 (2012), 828–838.
49. [49] Ness, K.K., Jones, K.E., Smith, W.A., Spunt, S.L., Wilson, C.L., Armstrong, G.T., et al. Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. Arch Phys Med Rehabil 94 (2013), 1451–1457.
50. [50] Hoffman, M.C., Mulrooney, D.A., Steinberger, J., Lee, J., Baker, K.S., Ness, K.K., Deficits in physical function among young childhood cancer survivors. J Clin Oncol: Official Journal of the American Society of Clinical Oncology 31 (2013), 2799–2805.
51. [51] Hartman, A., van den Bos, C., Stijnen, T., Pieters, R., Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer. Pediatr Blood Cancer 50 (2008), 833–837.
52. [52] Reinders-Messelink, H.A., Schoemaker, M.M., Hofte, M., Goeken, L.N., Kingma, A., van den Briel, M.M., et al. Fine motor and handwriting problems after treatment for childhood acute lymphoblastic leukemia. Med Pediatr Oncol 27 (1996), 551–555.
53. [53] Wright, M.J., Galea, V., Barr, R.D., Proficiency of balance in children and youth who have had acute lymphoblastic leukemia. Phys Ther 85 (2005), 782–790.
54. [54] NCI. Common terminology criteria for adverse events v4.03; 2010.
55. [55] Gilchrist, L.S., Marais, L., Tanner, L., Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 22 (2014), 359–366.
56. [56] Gilchrist, L.S., Tanner, L., The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 21 (2013), 847–856.
57. [57] Lavoie Smith, E.M., Li, L., Hutchinson, R.J., Ho, R., Burnette, W.B., Wells, E., et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 36 (2013), E49–E60.
58. [58] Bradfield, S.M., Sandler, E., Geller, T., Tamura, R.N., Krischer, J.P., Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer. Pediatr Blood Cancer 62 (2015), 1004–1010.
59. [59] Diouf, B., Crews, K.R., Lew, G., Pei, D., Cheng, C., Bao, J., et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313 (2015), 815–823.
60. [60] Reinders-Messelink, H.A., Schoemaker, M.M., Snijders, T.A., Goeken, L.N., Bokkerink, J.P., Kamps, W.A., Analysis of handwriting of children during treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 37 (2001), 393–399.
61. [61] Gilheeney, S.W., Lyden, D.C., Sgouros, S., Antunes, N., Gerald, W., Kramer, K., et al. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer 49 (2007), 261–265.
62. [62] Moriyama, B., Henning, S.A., Leung, J., Falade-Nwulia, O., Jarosinski, P., Penzak, S.R., et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 55 (2012), 290–297.
63. [63] Teusink, A.C., Ragucci, D., Shatat, I.F., Kalpatthi, R., Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 29 (2012), 62–67.
64. [64] Weintraub, M., Adde, M.A., Venzon, D.J., Shad, A.T., Horak, I.D., Neely, J.E., et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 14 (1996), 935–940.
65. [65] Bhushan, B., Bhargava, A., Kasundra, G.M., Shubhakaran, K., Sood, I., Guillain-Barre syndrome in acute lymphoblastic leukemia: Causal or coincidental. J Pediatr Neurosci 10 (2015), 64–66.
66. [66] Brigo, F., Balter, R., Marradi, P., Ferlisi, M., Zaccaron, A., Fiaschi, A., et al. Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia. J Child Neurol 27 (2012), 867–874.
67. [67] Ceppi, F., Langlois-Pelletier, C., Gagne, V., Rousseau, J., Ciolino, C., De Lorenzo, S., et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 15 (2014), 1105–1116.
68. [68] Trobaugh-Lotrario, A.D., Smith, A.A., Odom, L.F., Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol 40 (2003), 39–43.
69. [69] Mokhtar, G.M., Shaaban, S.Y., Elbarbary, N.S., Fayed, W.A., A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study. J Pediatr Hematol Oncol 32 (2010), 594–600.
70. [70] Akbayram, S., Akgun, C., Dogan, M., Sayin, R., Caksen, H., Oner, A.F., Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy. Indian J Pediatr 77 (2010), 681–683.
71. [71] Cavaletti, G., Cornblath, D.R., Merkies, I.S., Postma, T.J., Rossi, E., Frigeni, B., et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol: Official Journal of the European Society for Medical Oncology/ESMO 24 (2013), 454–462.
72. [72] Postma, T.J., Heimans, J.J., Muller, M.J., Ossenkoppele, G.J., Vermorken, J.B., Aaronson, N.K., Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol: Official Journal of the European Society for Medical Oncology/ESMO 9 (1998), 739–744.
73. [73] Klepper, S.E., Measures of pediatric function: Child Health Assessment Questionnaire (C-HAQ), Juvenile Arthritis Functional Assessment Scale (JAFAS), Pediatric Outcomes Data Collection Instrument (PODCI), and Activities Scale for Kids (ASK). Arthritis Care Res 63:Suppl 11 (2011), S371–S382.
74. [74] Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46 (2010), 479–494.
75. [75] Beutler, A.S., Kulkarni, A.A., Kanwar, R., Klein, C.J., Therneau, T.M., Qin, R., et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol 76 (2014), 727–737.
76. [76] Dobrozsi, S., Flood, V.H., Panepinto, J., Scott, J.P., Brandow, A., Vitamin B12 deficiency: the great masquerader. Pediatr Blood Cancer 61 (2014), 753–755.
77. [77] Hershman, D.L., Lacchetti, C., Dworkin, R.H., Lavoie Smith, E.M., Bleeker, J., Cavaletti, G., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol: Official Journal of the American Society of Clinical Oncology 32 (2014), 1941–1967.
78. [78] Sman, A.D., Hackett, D., Fiatarone Singh, M., Fornusek, C., Menezes, M.P., Burns, J., Systematic review of exercise for Charcot-Marie-Tooth disease. J Peripher Nerv Syst: JPNS 20 (2015), 347–362.